Targeting MRPs to overcome drug resistance is an area of active research. Inhibitors of MRPs are being developed to block the efflux function of these proteins, thereby increasing the intracellular concentration of chemotherapeutic drugs. Some of these inhibitors are currently in clinical trials, and early results are promising. However, specificity and toxicity are major concerns that need to be addressed.
